Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Condition:   Myelodysplastic Syndromes Interventions:   Drug: Canakinumab Injection;   Drug: Darbepoetin Alfa Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Novartis Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials